Pattern of drug use in the management of psoriasis in a tertiary care hospital: a prospective study


  • R. Raghunandan Department of Pharmacology, Dr. B.R. Ambedkar Medical College, Bengaluru, Karnataka, India
  • H. P. Pundarikaksha Department of Pharmacology, Kempegowda Institute of Medical Sciences, Bengaluru, Karnataka, India
  • M. G. Gopal Department of Dermatology and Venereology, Kempegowda Institute of Medical Sciences, Bengaluru, Karnataka, India


Psoriasis, Topical therapy, Systemic therapy, Phototherapy


Background: Psoriasis is a chronic skin disease, characterized by chronic and recurrent scaly plaques with itching. The treatment modalities for psoriasis include topical, systemic, and phototherapy (PT). The pattern of therapy may vary depending upon the type, severity, and duration of the disease. As there are few reports in the Indian literature regarding the pattern of drug use in psoriasis and evaluating the efficacy and patient compliance to treatment, the present study was conducted.

Methods: This was a prospective, observational study conducted on121 newly diagnosed and untreated patients with psoriasis, who attended Dermatology outpatient department of a tertiary care hospital. The severity of the disease was assessed by baseline psoriasis area severity index (PASI) score. Most of the patients were treated with topical therapy consisting of glucocorticoids (GC) monotherapy or combination with, salicylic acid, calcitriol and coal tar. Systemic therapy and PT were considered only for severe cases of psoriasis with baseline PASI score >4. The patients were monitored every 2 weeks for 3 months.

Results: The topical medications induced effective resolution of lesions in most of the patients, along with adequate symptomatic relief. The response to GC monotherapy was found significant (90.47%; p<0.001) and there was 76.13% decrease in PASI score in chronic plaque psoriasis, indicating significant improvement (p<0.001) after 12 weeks of therapy. More than 94% of study patients showed good compliance to medications and only 0.27% showed poor compliance, whereas the other patients showed a moderate compliance of 80-95%.

Conclusions: Most of the patients with psoriasis can be effectively treated with topical medications, and additional systemic and/or PT may be required only for severe cases of chronic plaque psoriasis with baseline score >4. Regular follow-up is required not only to monitor the treatment response, but also to ensure good patient compliance by proper counseling.


Bennett PN, Brown MJ. Clinical Pharmacology. 10th Edition. USA: Churchill Livingstone; 2008: 274-90.

Pavithran K, Karunakaran M, Palit A, Raghunatha S. Disorders of keratinization. In: Valia RG, Valia AR, editors. IADVL Textbook of Dermatology. 3rd Edition, Volume 1. Mumbai: Bhalani Publishing House; 2000: 1021-56.

Dogra S, Yadav S. Psoriasis in India: prevalence and pattern. Indian J Dermatol Venereol Leprol. 2010;76(6):595-601.

Sweetman SC, editor. Martindale: the Complete Drug Reference. 37th Edition. London: Pharmaceutical Press; 2011: 1762-3.

Mitra A, Wu Y. Topical delivery for the treatment of psoriasis. Expert Opin Drug Deliv. 2010;7(8):977-92.

Carretero G, Puig L, Dehesa L, Carrascosa JM, Ribera M, Sánchez-Regaña M, et al. Guidelines on the use of methotrexate in psoriasis. Actas Dermosifiliogr. 2010;101(7):600-13.

Bilac C, Ermertcan AT, Bilac DB, Deveci A, Horasan GD. The relationship between symptoms and patient characteristics among psoriasis patients. Indian J Dermatol Venereol Leprol. 2009;75(5):551.

Yap FB, Pubalan M. Pattern and clinical characteristics of patients with nail psoriasis in Sarawak General Hospital, Malaysia. Indian J Dermatol Venereol Leprol. 2010;76(6):703-4.

Christophers E. Defining psoriasis subtypes: features of severe psoriasis and associated disease. Expert Rev Dermatol. 2007;2(1):13-7.

Kaur I, Kumar B, Sharma KV, Kaur S. Epidemiology of psoriasis in a clinic from North India. Indian J Dermatol Venerol Leprol. 1986;52(4):208-12.

Ghosal A, Gangopadhyay DN, Chanda M, Das NK. Study of nail changes in psoriasis. Indian J Dermatol. 2004;49(1):18-21.

Dogra S, De D. Narrowband ultraviolet B in the treatment of psoriasis: the journey so far! Indian J Dermatol Venereol Leprol. 2010;76(6):652-61.

Kumar A, Mohan L, Singh KK, Pandey ON, Mu. Mode of inheritance in psoriasis. Indian J Dermatol Venereol Leprol. 1992;58(3):179-82.

Chatterjee M, Parashar R, Satish DA, Haldar S. Topical treatment of psoriasis- from old to gold. Proceedings of the Symposium for Psoriasis and Atopic Dermatitis Excellence (SPADE); 2010 Oct 31st. Mumbai, Delhi, Hyderabad, Kolkata; India: Aramuc India Ltd.; 2010.

Khanna N, Tejasvi TR. Step by Step Psoriasis Management. 1st Edition. New Delhi: Jaypee Brothers Medical Publishers; 2012.

Mehta S, Singal A, Singh N, Bhattacharya SN. A study of clinicohistopathological correlation in patients of psoriasis and psoriasiform dermatitis. Indian J Dermatol Venereol Leprol. 2010;76(6):622-32.

Gupta SK, Singh KK, Lalit M. Comparative therapeutic evaluation of different topicals and narrow band ultraviolet B therapy combined with systemic methotrexate in the treatment of palmoplantar psoriasis. Indian J Dermatol. 2011;56(2):165-70.

Bedi TR. Clinical profile of psoriasis in North India. Indian J Dermatol Venereol Leprol. 1995;61(4):202-5.

Laws PM, Young HS. Topical treatment of psoriasis. Expert Opin Pharmacother. 2010;11(12):1999-2009.

Gupta AK, Ellis CN, Siegel MT, Duell EA, Griffiths CE, Hamilton TA, et al. Sulfasalazine improves psoriasis. A double-blind analysis. Arch Dermatol. 1990;126(4):487-93.

Pujara S, Sekhri R, Parthasarathi A, Hauelia D. Systemic therapy in psoriasis. Proceedings of the Symposium for Psoriasis and Atopic Dermatitis Excellence (SPADE); 2010 Oct 31st. Mumbai, Delhi, Hyderabad, Kolkata; India: Aramuc India Ltd.; 2010.

Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis. Expert Rev Dermatol. 2006;1(1):63-75.

Naldi L, Yawalkar N, Kaszuba A, Ortonne JP, Morelli P, Rovati S, et al. Efficacy and safety of the Betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis: a randomized, parallel-group, active-controlled, phase III study. Am J Clin Dermatol. 2011;12(3):191-201.

Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am J Clin Dermatol. 2009;10(6):397-406.

Alora-Palli MB, Perkins AC, Van Cott A, Kimball AB. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. Am J Clin Dermatol. 2010;11(4):275-83.

Koek MB, Buskens E, van Weelden H, Steegmans PH, Bruijnzeel-Koomen CA, Sigurdsson V. Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study). BMJ. 2009;338:b1542.

McCormack PL. Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp. Drugs. 2011;71(6):709-30.

Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537-41.




How to Cite

Raghunandan, R., Pundarikaksha, H. P., & Gopal, M. G. (2017). Pattern of drug use in the management of psoriasis in a tertiary care hospital: a prospective study. International Journal of Basic & Clinical Pharmacology, 3(4), 611–618. Retrieved from



Original Research Articles